DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's oncolytic viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches. 
Technology
DNAtrix is developing potent oncolytic immunotherapies for the treatment of cancer using genetically modified viruses that maximize safety and efficacy.
learn more >
November 15, 2018DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma
November 13, 2018DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
November 7, 2018Effectiveness of DNAtrix’s DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at SITC 2018
DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's oncolytic viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches. learn more >
Pipeline
A pipeline of novel viral-driven immunotherapies is being developed for the treatment of a variety of aggressive cancers.
learn more >
For Patients
Human clinical trials of DNAtrix therapies are ongoing for adult and pediatric patients diagnosed with aggressive brain tumors.
learn more >
Virus artwork by Luke Jerram